~~<i id='F71A20A754'><strike id='F71A20A754'><tt id='F71A20A754'><pre id='F71A20A754'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

entertainment

author：Wikipedia 2025-09-14 14:45:22 - browse：14343

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

entertainment

Wikipedia

explore

knowledge

explore

hotspot

ChrisO'Meara/APJohnson&Johnsonfacesaconsequentialnewclassactionlawsuit—notinitsroleasamanuf

WSS

Top private equity targets in 2023: cardiology, clinical trials, lasers

Johnson & Johnson sued for allegedly overpaying for workers' drugs

CMS should re

Gene therapy for Afghan refugees’ infant will be fully covered

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

The CDC's new social media misinformation war

leisure time

entertainment

entertainment

Medicare details structure of new drug price negotiation program

CMS should re

In Memoriam: Notable people who died in 2023

Pregnancy discrimination could be enabled by AI

United colonoscopy coverage change 'may cost lives,' doctors say

Cano Health’s bankruptcy is a warning for Medicare Advantage

Wildfire smoke exposes gaps in outdoor worker protections

What’s missing from the debate over nursing home staff minimums

Supreme Court strikes down use of affirmative action

AI models in health care face new federal disclosure requirements

Wikipedia

Americans' trust in science, scientist continues decline: Report

Devoted Health’s losses in Medicare Advantage persist

Medicare Advantage plans can’t deny care with AI, CMS warns

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Congenital heart disease patients face new threat of heart failure

The woman behind the Dana Farber

explore

knowledge

explore

hotspot